ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

clazakizumab

Also written as “BMS-945429”, “ALD518” and “Clazakizumab”.

Its studies are mostly in Arthritis, Rheumatoid · Atherosclerosis · Crohn Disease · Arthritis, Psoriatic · Stomatitis, led by 2 companies.

Drug pageClazakizumab: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 6, 201810 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSLits history only90 open or runningphase 3since Nov 6, 2018Mar 20, 2009none ahead
Eli Lilly11 open or runningphase 2since Aug 21, 2026Aug 21, 2026May 2027phase 2 · NCT07783802
  • Named in Eli Lilly’s own pipeline as Clazakizumab, phase 2, as of Oct 29, 2026 (source).

Also a collaborator on its studies: ICON Clinical Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2026First study: phase 2 study in AtherosclerosisFirst studyNCT07783802 · 120 planned · United States, Argentina, Japan and more

Ahead

  1. May 2027Primary completion: phase 2 study in AtherosclerosisNCT07783802

TargetBeta

“A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (Il-6) with potential immunomodulating activity. Upon administration, clazakizumab binds to and blocks the activity of IL-6, which may mitigate the catabolic effects of IL-6.”NCIt, read by Claude
“Interleukin-6 inhibitor”ChEMBL 37, by rule

Other programs on IL6

ProgramCompanyFurthest phaseStudies
olokizumabruleR-Pharmphase 319
ziltivekimabruleNovo Nordiskphase 312
pacibekitugruleNovartisphase 31
isomyosamineruletnf-pharmaceuticals-incphase 21

Studies

The one study Eli Lilly leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07783802Atherosclerosis · United States, Argentina, Japan and more2RecruitingMay 2027120

How it is read

Names in the registry

  • “BMS-945429”, 16 entries
  • “ALD518”, 8 entries
  • “Clazakizumab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.